Form 4: Werewolf Therapeutics Director Luke Evnin Exercises Warrants and Sells Shares

Director Luke Evnin reports exercising warrants and selling shares of Werewolf Therapeutics, Inc.

Summary

• On March 27, 2025, Luke Evnin, a director of Werewolf Therapeutics, Inc., exercised warrants to purchase 28,113 shares of common stock at $0.09 per share.
• The exercise was done on a cashless basis, resulting in the company withholding 2,425 shares to cover the exercise price.
• Evnin then sold 2,425 shares at $1.05 per share.
• Following these transactions, Evnin indirectly beneficially owns 4,309,860 shares.
• Evnin also indirectly holds warrants to purchase 4,015 and 24,098 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports transactions. There is no indication of positive or negative outlook.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the biopharmaceutical industry. Monitoring such transactions can provide insights into management's perspective on the company's value and prospects.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the potential dilution from warrant exercises and the signal from the share sale.

Key Dates

Keywords

Werewolf Therapeutics, Luke Evnin, Form 4, Warrants, Share Sale, Beneficial Ownership, Director, HOWL